• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

TNFα 是饮食诱导的非肥胖 MASLD 小鼠炎症反应的关键触发因素。

TNFα is a key trigger of inflammation in diet-induced non-obese MASLD in mice.

机构信息

Department of Nutritional Sciences, Molecular Nutritional Science, University of Vienna, Vienna, Austria.

Department of Nutritional Sciences, Molecular Nutritional Science, University of Vienna, Vienna, Austria.

出版信息

Redox Biol. 2023 Oct;66:102870. doi: 10.1016/j.redox.2023.102870. Epub 2023 Sep 1.

DOI:10.1016/j.redox.2023.102870
PMID:37683301
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10493600/
Abstract

Tumor necrosis factor alpha (TNFα) is thought to be a critical factor in the development of metabolic dysfunction-associated steatotic liver disease (MASLD). Here, we determined the effects of a treatment with the anti-TNFα antibody infliximab and a genetic deletion of TNFα, respectively, in the development of non-obese diet-induced early metabolic dysfunction-associated steatohepatitis (MASH) in mice. The treatment with infliximab improved markers of liver damage in mice with pre-existing early MASH. In TNFα mice, the development of early signs of MASH and insulin resistance was significantly attenuated compared to wild-type animals. While mRNA expression of proinflammatory cytokines like interleukin 1β (Il1b) and interleukin 6 (Il6) were significantly lower in livers of MASH-diet-fed TNFα mice compared to wild-type mice with early MASH, markers of intestinal barrier function were similarly impaired in both MASH-diet-fed groups compared to controls. Our data suggest that TNFα is a key regulator of hepatic inflammation and insulin resistance associated with the development of early non-obese MASH.

摘要

肿瘤坏死因子-α(TNFα)被认为是代谢功能障碍相关脂肪性肝病(MASLD)发展的关键因素。在这里,我们分别确定了抗 TNFα 抗体英夫利昔单抗治疗和 TNFα 基因缺失对非肥胖饮食诱导的早期代谢功能障碍相关脂肪性肝炎(MASH)在小鼠中的发展的影响。英夫利昔单抗治疗改善了患有早期 MASH 的小鼠的肝损伤标志物。与野生型动物相比,TNFα 小鼠的早期 MASH 体征和胰岛素抵抗的发展明显减弱。尽管 MASH 饮食喂养的 TNFα 小鼠肝脏中促炎细胞因子(如白细胞介素 1β(Il1b)和白细胞介素 6(Il6))的 mRNA 表达明显低于早期 MASH 的野生型小鼠,但两组 MASH 饮食喂养的小鼠的肠道屏障功能标志物与对照组相比均有类似的损害。我们的数据表明,TNFα 是与早期非肥胖性 MASH 发展相关的肝炎症和胰岛素抵抗的关键调节剂。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5da6/10493600/445868f14d41/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5da6/10493600/63a96e39a211/ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5da6/10493600/c45790243b8f/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5da6/10493600/5bbb59740888/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5da6/10493600/2fd78446143c/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5da6/10493600/445868f14d41/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5da6/10493600/63a96e39a211/ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5da6/10493600/c45790243b8f/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5da6/10493600/5bbb59740888/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5da6/10493600/2fd78446143c/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5da6/10493600/445868f14d41/gr4.jpg

相似文献

1
TNFα is a key trigger of inflammation in diet-induced non-obese MASLD in mice.TNFα 是饮食诱导的非肥胖 MASLD 小鼠炎症反应的关键触发因素。
Redox Biol. 2023 Oct;66:102870. doi: 10.1016/j.redox.2023.102870. Epub 2023 Sep 1.
2
MASLD is related to impaired alcohol dehydrogenase (ADH) activity and elevated blood ethanol levels: Role of TNFα and JNK.MASLD 与乙醇脱氢酶(ADH)活性受损和血液乙醇水平升高有关:TNFα 和 JNK 的作用。
Redox Biol. 2024 May;71:103121. doi: 10.1016/j.redox.2024.103121. Epub 2024 Mar 12.
3
Sex-based differences in natural killer T cell-mediated protection against diet-induced steatohepatitis in Balb/c mice.基于性别的差异,自然杀伤 T 细胞在保护 Balb/c 小鼠抵抗饮食诱导的脂肪性肝炎中的作用。
Biol Sex Differ. 2023 Nov 14;14(1):85. doi: 10.1186/s13293-023-00569-w.
4
The potential role of omentin-1 in obesity-related metabolic dysfunction-associated steatotic liver disease: evidence from translational studies.网膜素-1 在肥胖相关代谢功能障碍相关脂肪性肝病中的潜在作用:来自转化研究的证据。
J Transl Med. 2023 Dec 11;21(1):906. doi: 10.1186/s12967-023-04770-8.
5
Suppression of STK39 weakens the MASLD/MASH process by protecting the intestinal barrier.抑制 STK39 通过保护肠道屏障来减弱 MASLD/MASH 进程。
Biosci Trends. 2024 Jul 9;18(3):289-302. doi: 10.5582/bst.2024.01097. Epub 2024 Jun 26.
6
Genetic Ablation of STE20-Type Kinase MST4 Does Not Alleviate Diet-Induced MASLD Susceptibility in Mice.遗传敲除 STE20 型激酶 MST4 不能减轻小鼠饮食诱导的 MASLD 易感性。
Int J Mol Sci. 2024 Feb 19;25(4):2446. doi: 10.3390/ijms25042446.
7
Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases.代谢功能障碍相关脂肪性肝病(MASLD)和代谢功能障碍相关脂肪性肝炎(MASH)对心脏、肌肉和肾脏相关疾病的全身影响。
Front Cell Dev Biol. 2024 Jul 16;12:1433857. doi: 10.3389/fcell.2024.1433857. eCollection 2024.
8
Probiotic Mixture Ameliorates a Diet-Induced MASLD/MASH Murine Model through the Regulation of Hepatic Lipid Metabolism and the Gut Microbiome.益生菌混合物通过调节肝脂代谢和肠道微生物群改善饮食诱导的 MASLD/MASH 小鼠模型。
J Agric Food Chem. 2024 Apr 17;72(15):8536-8549. doi: 10.1021/acs.jafc.3c08910. Epub 2024 Apr 4.
9
Ablation of IFNγ in myeloid cells suppresses liver inflammation and fibrogenesis in mice with hepatic small heterodimer partner (SHP) deletion.髓系细胞中 IFNγ 的缺失可抑制肝小异二聚体伴侣 (SHP)缺失小鼠的肝脏炎症和肝纤维化。
Mol Metab. 2024 May;83:101932. doi: 10.1016/j.molmet.2024.101932. Epub 2024 Apr 6.
10
Histidine-rich glycoprotein in metabolic dysfunction-associated steatohepatitis-related disease progression and liver carcinogenesis.富含组氨酸糖蛋白在代谢功能障碍相关脂肪性肝炎相关疾病进展及肝癌发生中的作用
Front Immunol. 2024 Feb 26;15:1342404. doi: 10.3389/fimmu.2024.1342404. eCollection 2024.

引用本文的文献

1
Metabolic Dysfunction-Associated Steatotic Liver Disease: A Silent Driver of Cardiovascular Risk and a New Target for Intervention.代谢功能障碍相关脂肪性肝病:心血管风险的隐匿驱动因素及新的干预靶点
Int J Mol Sci. 2025 Aug 21;26(16):8081. doi: 10.3390/ijms26168081.
2
Metabolic-dysfunction associated steatotic liver disease and atrial fibrillation: A review of pathogenesis.代谢功能障碍相关脂肪性肝病与心房颤动:发病机制综述
World J Cardiol. 2025 Jun 26;17(6):106147. doi: 10.4330/wjc.v17.i6.106147.
3
Targeting Metabolism: Innovative Therapies for MASLD Unveiled.

本文引用的文献

1
Reply: A multi-society Delphi consensus statement on new fatty liver disease nomenclature.回复:关于新的脂肪性肝病命名的多学会德尔菲共识声明。
Hepatology. 2024 Mar 1;79(3):E93-E94. doi: 10.1097/HEP.0000000000000696. Epub 2023 Nov 20.
2
Effect of Dietary Intervention, with or without Cointerventions, on Inflammatory Markers in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.膳食干预及其联合干预对非酒精性脂肪性肝病患者炎症标志物的影响:系统评价和荟萃分析。
Adv Nutr. 2023 May;14(3):475-499. doi: 10.1016/j.advnut.2023.01.001. Epub 2023 Feb 1.
3
Nonalcoholic Fatty Liver Disease in Lean/Nonobese and Obese Individuals: A Comprehensive Review on Prevalence, Pathogenesis, Clinical Outcomes, and Treatment.
靶向代谢:非酒精性脂肪性肝炎的创新疗法揭秘。
Int J Mol Sci. 2025 Apr 25;26(9):4077. doi: 10.3390/ijms26094077.
4
Metabolic dysfunction-associated steatotic liver disease and increased risk of atrial fibrillation in the elderly: A longitudinal cohort study.代谢功能障碍相关脂肪性肝病与老年人房颤风险增加:一项纵向队列研究。
Int J Cardiol Heart Vasc. 2025 Apr 8;58:101676. doi: 10.1016/j.ijcha.2025.101676. eCollection 2025 Jun.
5
Associations of the Intake of Individual and Multiple Flavonoids with Metabolic Dysfunction Associated Steatotic Liver Disease in the United States.美国个体及多种类黄酮摄入量与代谢功能障碍相关脂肪性肝病的关联
Nutrients. 2025 Jan 7;17(2):205. doi: 10.3390/nu17020205.
6
Limited preventive effects of empagliflozin against metabolic dysfunction-associated steatotic liver disease in a mouse model of fast food diet.在快餐饮食小鼠模型中,恩格列净对代谢功能障碍相关脂肪性肝病的预防作用有限。
Hormones (Athens). 2024 Dec 19. doi: 10.1007/s42000-024-00621-3.
7
A weekly 4-methylpyrazole treatment attenuates the development of non-obese metabolic dysfunction-associated steatotic liver disease (MASLD) in male mice: Role of JNK.每周一次的4-甲基吡唑治疗可减轻雄性小鼠非肥胖代谢功能障碍相关脂肪性肝病(MASLD)的发展:JNK的作用
Eur J Clin Invest. 2025 Jan;55(1):e14320. doi: 10.1111/eci.14320. Epub 2024 Sep 29.
8
Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review.代谢功能障碍相关脂肪性肝病与心血管风险:全面综述。
Cardiovasc Diabetol. 2024 Sep 28;23(1):346. doi: 10.1186/s12933-024-02434-5.
9
MASLD does not affect fertility and senolytics fail to prevent MASLD progression in male mice.MASLD 并不影响生育能力,衰老抑制剂也不能阻止雄性小鼠 MASLD 的进展。
Sci Rep. 2024 Jul 27;14(1):17332. doi: 10.1038/s41598-024-67697-0.
瘦/非肥胖和肥胖个体中的非酒精性脂肪性肝病:关于患病率、发病机制、临床结局及治疗的综合综述
J Clin Transl Hepatol. 2023 Apr 28;11(2):502-515. doi: 10.14218/JCTH.2022.00204. Epub 2022 Dec 23.
4
The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review.非酒精性脂肪性肝病(NAFLD)和非酒精性脂肪性肝炎(NASH)的全球流行病学:系统评价。
Hepatology. 2023 Apr 1;77(4):1335-1347. doi: 10.1097/HEP.0000000000000004. Epub 2023 Jan 3.
5
Gut-liver axis: Pathophysiological concepts and clinical implications.肠-肝轴:病理生理概念及临床意义。
Cell Metab. 2022 Nov 1;34(11):1700-1718. doi: 10.1016/j.cmet.2022.09.017. Epub 2022 Oct 7.
6
Under the Umbrella of Clinical Pharmacology: Inflammatory Bowel Disease, Infliximab and Adalimumab, and a Bridge to an Era of Biosimilars.在临床药理学的框架下:炎症性肠病、英夫利昔单抗和阿达木单抗,以及通往生物类似药时代的桥梁。
Pharmaceutics. 2022 Aug 24;14(9):1766. doi: 10.3390/pharmaceutics14091766.
7
AGA Clinical Practice Update: Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert Review.AGA 临床实践更新:瘦个体中非酒精性脂肪性肝病的诊断和管理:专家评论。
Gastroenterology. 2022 Sep;163(3):764-774.e1. doi: 10.1053/j.gastro.2022.06.023. Epub 2022 Jul 14.
8
Demonstration of Gut-Barrier Dysfunction in Early Stages of Non-alcoholic Fatty Liver Disease: A Proof-Of-Concept Study.非酒精性脂肪性肝病早期肠道屏障功能障碍的证明:一项概念验证研究。
J Clin Exp Hepatol. 2022 Jul-Aug;12(4):1102-1113. doi: 10.1016/j.jceh.2022.01.006. Epub 2022 Jan 24.
9
The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis.全球非酒精性脂肪性肝病的患病率和发病率:系统评价和荟萃分析。
Lancet Gastroenterol Hepatol. 2022 Sep;7(9):851-861. doi: 10.1016/S2468-1253(22)00165-0. Epub 2022 Jul 5.
10
Alterations of nitric oxide homeostasis as trigger of intestinal barrier dysfunction in non-alcoholic fatty liver disease.一氧化氮动态平衡的改变作为非酒精性脂肪性肝病肠道屏障功能障碍的触发因素。
J Cell Mol Med. 2022 Feb;26(4):1206-1218. doi: 10.1111/jcmm.17175. Epub 2022 Jan 14.